Clinical Trial Update: Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase II study of Taxotere (docetaxel) in combination with Exisulind in non-small cell lung cancer has completed. The entry notes the trial status but does not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Exisulind (exisulind)
• Taxotere (docetaxel)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: NSCLC | Phase 1, Phase 2 | Status: COMPLETED